Filing Details
- Accession Number:
- 0001062993-23-015315
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-07-25 17:27:42
- Reporting Period:
- 2023-07-21
- Accepted Time:
- 2023-07-25 17:27:42
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 842023 | Bio-Techne Corp | TECH | Biological Products, (No Disgnostic Substances) (2836) | 411427402 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1534980 | R. Charles Kummeth | 614 Mckinley Place Ne Minneapolis MN 55413 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Disposition | 2023-07-21 | 80,000 | $88.36 | 1,258,766 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | S | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 400 | Indirect | By Step-Son |
| Common Stock | 400 | Indirect | By Step-Daughter |
Reported Derivative Holdings
| Sec. Name | Sec. Type | Price | Date | Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (Right to Buy) | $31.26 | 2024-08-09 | 779,084 | 779,084 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $44.33 | 2025-08-08 | 361,336 | 361,336 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $44.33 | 2025-08-08 | 240,888 | 240,888 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $47.60 | 2026-08-07 | 342,900 | 342,900 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 52,900 | 52,900 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $47.60 | 2026-08-07 | 228,600 | 228,600 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 51,516 | 51,516 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $66.97 | 2027-08-05 | 299,768 | 299,768 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $66.97 | 2027-08-05 | 153,180 | 153,180 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $66.97 | 2027-08-05 | 66,600 | 66,600 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $66.97 | 2027-08-05 | 66,600 | 66,600 | Direct | |
| Common Stock | Restricted Stock Units | $0.00 | 32,064 | 32,064 | Direct | ||
| Common Stock | Stock Options (Right to Buy) | $120.46 | 2028-08-06 | 125,260 | 125,260 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $120.46 | 2028-08-06 | 83,504 | 83,504 | Direct | |
| Common Stock | Stock Options (Right to Buy) | $94.52 | 2029-08-15 | 1,200,000 | 1,200,000 | Direct |
| Expiration Date | Amount | Remaning Holdings | Nature of Ownership |
|---|---|---|---|
| 2024-08-09 | 779,084 | 779,084 | Direct |
| 2025-08-08 | 361,336 | 361,336 | Direct |
| 2025-08-08 | 240,888 | 240,888 | Direct |
| 2026-08-07 | 342,900 | 342,900 | Direct |
| 52,900 | 52,900 | Direct | |
| 2026-08-07 | 228,600 | 228,600 | Direct |
| 51,516 | 51,516 | Direct | |
| 2027-08-05 | 299,768 | 299,768 | Direct |
| 2027-08-05 | 153,180 | 153,180 | Direct |
| 2027-08-05 | 66,600 | 66,600 | Direct |
| 2027-08-05 | 66,600 | 66,600 | Direct |
| 32,064 | 32,064 | Direct | |
| 2028-08-06 | 125,260 | 125,260 | Direct |
| 2028-08-06 | 83,504 | 83,504 | Direct |
| 2029-08-15 | 1,200,000 | 1,200,000 | Direct |
Footnotes
- The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 7, 2022.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $88.00 to $88.95 inclusive. The reporting person undertakes to provide Bio-Techne Corporation, any security holder of Bio-Techne Corporation, or the staff of the Securities and Exchange Commission upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- Includes (i) 11,448 shares of restricted stock for which the risk of forfeiture will lapse on August 5, 2023; and (ii) 14,248 shares of restricted stock for which the risk of forfeiture will lapse as to 7,128 shares on each of August 6, 2023 and August 6, 2024.
- Fully exercisable.
- Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
- 17,632 shares vest on each of 8/15/2023 and 8/15/2025, and 17,636 shares vest on 8/15/2024.
- Options to purchase 57,152 shares vest on each of 8/7/2020 and 8/7/2021 and options to purchase 57,148 shares vest on each of 8/7/2022 and 8/7/2023.
- Vests in full or in part on 8/5/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 38,292 shares vest on 8/5/21 and options to purchase 38,296 shares vest on each of 8/5/22, 8/5/23 and 8/5/24.
- Vests in full on the date performance of certain product revenue goals during the period of fiscal 2021-2023 is certified by the Administrator, in no event earlier than 8/5/2021.
- Options to purchase 22,200 shares vest on each of 8/5/21, 8/5/22 and 8/5/23.
- Vests in full or in part on 8/6/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- Options to purchase 20,876 shares vest on each of 8/6/2022, 8/6/2023, 8/6/2024 and 8/6/2025.
- 600,000 options vest in full or in part on 7/1/2023 if certain performance goals are achieved (or such later date as performance is certified by the Administrator), and 600,000 options vest in full or in part on 7/1/2024 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
Billionaire Hedge Funds
